Clearmind Medicine INC. (CMND) SEC Filings — 2024
40 SEC filings for Clearmind Medicine INC. (CMND) in 2024.
Filings
- Clearmind Medicine Gets IRB Approval for FDA Clinical Trial — 6-K · Dec 26, 2024
- Clearmind Medicine Schedules Shareholder Meeting for Jan 6, 2025 — 6-K · Dec 6, 2024
- Clearmind Medicine Sets Jan 6 Shareholder Meeting — 6-K · Nov 20, 2024
- Clearmind Medicine INC. SC 13G/A Filing — SC 13G/A · Nov 14, 2024
- Clearmind Medicine Gets IRB Approval for Second Clinical Trial Site — 6-K · Oct 10, 2024
- Clearmind Medicine Appoints New Board Member — 6-K · Sep 26, 2024
- Clearmind Medicine Files Interim Financials — 6-K · Sep 16, 2024
- Clearmind Medicine Files International Patent for PTSD Psychedelics — 6-K · Sep 12, 2024
- Clearmind Medicine Files International Patent for MDMA-Based Alcohol Treatment — 6-K · Sep 6, 2024
- Clearmind Medicine Patent Application Published — 6-K · Aug 29, 2024
- Clearmind Medicine Gets US Patent for Binge Behavior Treatment — 6-K · Aug 21, 2024
- Clearmind Medicine Inc. Updates Corporate Presentation — 6-K · Aug 20, 2024
- Clearmind & Yissum Patent Psychedelic Compounds — 6-K · Aug 16, 2024
- Clearmind Medicine's MEAI Shows Weight Loss Potential in New Study — 6-K · Aug 6, 2024
- Clearmind Secures Manufacturing and Distribution for Alcohol Substitute — 6-K · Jul 19, 2024
- Clearmind Medicine Secures FDA IND Approval for Alcoholism Trial — 6-K · Jul 16, 2024
- Clearmind Medicine Secures Hong Kong Patent for Binge Behavior Treatment — 6-K · Jun 28, 2024
- Clearmind Enters $13B Non-Alcoholic Drink Market — 6-K · Jun 13, 2024
- Clearmind Medicine Advances Psychedelic Alcohol Beverage — 6-K · May 10, 2024
- Clearmind Secures Global Psychedelic Rights for PTSD — 6-K · May 7, 2024
- Clearmind Medicine Seeks to Cease Canadian Reporting Issuer Status — 6-K · Apr 30, 2024
- Clearmind Medicine Licenses Psychedelic Compounds — 6-K · Apr 17, 2024
- Clearmind Medicine Files US Patent for Psychedelic Eating Disorder Treatment — 6-K · Apr 10, 2024
- Clearmind Medicine CEO Addresses Shareholders in 6-K Filing — 6-K · Apr 9, 2024
- Clearmind Medicine Inc. Files Amendment to Annual Report — 20-F/A · Mar 27, 2024
- Clearmind Medicine Files Q3 Financials — 6-K · Mar 19, 2024
- Clearmind Medicine Inc. Files Amendment to Annual Report — 20-F/A · Mar 18, 2024
- Clearmind Medicine to Delist from CSE, Focus on Nasdaq — 6-K · Mar 13, 2024
- Clearmind Files 3 New Psychedelic Compound Patents — 6-K · Feb 27, 2024
- Clearmind Medicine Gets Green Light for CMND-100 Clinical Trial — 6-K · Feb 23, 2024
- Clearmind Medicine Files 3 International Psychedelic Patent Applications — 6-K · Feb 20, 2024
- Clearmind Medicine INC. SC 13G Filing — SC 13G · Feb 14, 2024
- Clearmind Medicine Regains Nasdaq Compliance with $7M Equity — 6-K · Feb 9, 2024
- Intracoastal Capital, Kopin Reduce Clearmind Medicine Stake to 4.99% — SC 13G/A · Feb 6, 2024
- Clearmind Medicine Secures China Patent for Binge Behavior Treatment — 6-K · Feb 5, 2024
- Clearmind Medicine Secures Exclusive Licensing Deal with Israeli Research Center — 6-K · Feb 1, 2024
- Clearmind Medicine Inc. Files Annual Report on Form 20-F for Fiscal Year Ended October 31, 2023 — 20-F · Jan 29, 2024
- Iroquois Capital Discloses 282,952 Share Stake in Clearmind Medicine — SC 13G · Jan 22, 2024
- Clearmind Medicine Prices $1.60 Registered Direct Offering & Private Placement — 6-K · Jan 16, 2024
- Clearmind Medicine Completes Key FDA Type A Meeting — 6-K · Jan 10, 2024